Tvardi Therapeutics Inc. TVRD 深 沪
交易中 05-19 10:46:34 美东时间
3.975
-0.025
-0.62%
华盛通- 最 高4.00
- 今 开3.98
- 成交量 3811股
- 最 低 3.90
- 昨 收 4.00
- 总市值 3729.08万
- 52周最高 43.65
- 市盈率 静 --
- 换手率 0.04%
- 52周最低 2.75
- 委 比 -37.41%
- 总股本 938.13万
- 历史最高 1067.292
- 量 比 0.73
- 振 幅 2.50%
- 历史最低 2.75
- 每 手 1
- 风险率 12.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tvardi Therapeutics Q1 EPS $(0.73) Beats $(0.74) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.74) by 1.35 percent. This is a 77.33 percent increase over losses of $(3.22) per share
05-08 19:11
Tvardi Therapeutics Files Prospectus For Offering $200M Mixed Shelf
https://www.sec.gov/Archives/edgar/data/1346830/000110465926054113/tm2613101-1_s3.htm
05-02 04:11
美股大行评级 | 大摩上调Lumentum目标价从595美元升至710美元；康宁、道富银行、Ally Financial获多家机构上调目标价
今日重点评级关注：Canaccord Genuity：维持Vertical Aerospace"买入"评级，目标价从9.5美元升至10.5美元；Canaccord Genuity：维持AtaiBeckley Inc."买入"评级，目标价从14美元升至15美元
04-21 11:25
Barclays Downgrades Tvardi Therapeutics to Underweight, Lowers Price Target to $3
Barclays analyst Etzer Darout downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Equal-Weight to Underweight and lowers the price target from $4 to $3.
04-20 21:15
美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
Piper Sandler Maintains Neutral on Tvardi Therapeutics, Lowers Price Target to $3
Piper Sandler analyst Yasmeen Rahimi maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Neutral and lowers the price target from $4 to $3.
04-02 01:57
Tvardi Therapeutics Q4 EPS $(0.78) Misses $(0.68) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.68) by 15.38 percent. This is a 84.21 percent increase over losses of $(4.94) per share
04-01 05:14
Tvardi Therapeutics Provides Updates From Phase 2 REVERT IPF Clinical Trial Of TTI-101 In Idiopathic Pulmonary Fibrosis
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo groupTopline healthy volunteer data from Phase 1 study of
01-08 21:13
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you ...
2025-11-30 22:46
Tvardi Therapeutics Q3 EPS $(0.59) Beats $(0.92) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.92) by 35.8 percent.
2025-11-14 05:32
